Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing
XX min read
TL;DR
Oops! Something went wrong while submitting the form.
Share on Social
More media
December 9, 2025
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies
Press
December 9, 2025
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies
Press
